Coya Therapeutics announces $5M strategic investment from ADDF

Coya Therapeutics, announces that the Alzheimer’s Drug Discovery Foundation ADDF has purchased 603,136 shares of the Company’s common stock at a purchase price of $8.29 per share for an aggregate investment of $5M. ADDF’s mission is to rapidly accelerate the development of drugs to prevent, treat, and cure Alzheimer’s disease and related dementias, including FTD. Coya‘s lead therapeutic candidate, COYA 302, is being evaluated in multiple neurodegenerative diseases, including FTD, and the Company intends for this equity investment to help fund the development of COYA 302 in a planned Phase 2 trial in FTD. … The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the securities issued to ADDF no later than 30 days following the date of the definitive agreements and to have the registration statement declared effective no later than 75 days following the date of the definitive agreements in the event of a “full review” by the SEC.